ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0RN3 Takeda Pharmaceutical Co Ltd

49.35
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Takeda Pharmaceutical Co Ltd LSE:0RN3 London Ordinary Share JP3463000004 TAKEDA PHARMACEUTICAL ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 49.35 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.05T 317.02B 200.3525 0.14 45.02B

Morgan Stanley & Co. Int'l plc Form 8.5 (EPT/RI) - Replacement of Takeda (7853M)

10/01/2019 1:40pm

UK Regulatory


Takeda Pharmaceutical (LSE:0RN3)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Takeda Pharmaceutical Charts.

TIDM48QN TIDM0RN3

RNS Number : 7853M

Morgan Stanley & Co. Int'l plc

10 January 2019

   AMENDMENT       Section (2a) 

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

   1.         KEY INFORMATION 
 
 (a) Name of exempt principal trader:                                           Morgan Stanley & Co. International plc 
 (b) Name of offeror/offeree in relation to whose relevant securities this      Takeda Pharmaceutical Company Limited 
 form relates: 
 Use a separate form for each offeror/offeree 
                                                                               --------------------------------------- 
 (c) Name of the party to the offer with which exempt principal trader is       Shire plc 
 connected: 
                                                                               --------------------------------------- 
 (d) Date dealing undertaken:                                                   07 JANUARY 2019 
                                                                               --------------------------------------- 
 (e) In addition to the company in 1(b) above, is the exempt principal trader   Yes - Shire plc 
 making disclosures 
 in respect of any other party to this offer? 
 If it is a cash offer or possible cash offer, state "N/A" 
                                                                               --------------------------------------- 
 
   2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

   (a)        Purchases and sales 
 
 Class of    Purchases/    Total number         Highest price             Lowest price 
  relevant      sales      of securities    per unit paid/received    per unit paid/received 
  security 
 Ordinary    PURCHASES       509,317             4,074.0000                3,908.0000 
                                                     JPY                       JPY 
            -----------  ---------------  ------------------------  ------------------------ 
 Ordinary      SALES         541,717             4,074.0000                3,923.0000 
                                                     JPY                       JPY 
            -----------  ---------------  ------------------------  ------------------------ 
 Ordinary    PURCHASES        49,600             36.8971 USD               36.7058 USD 
            -----------  ---------------  ------------------------  ------------------------ 
 
   (b)        Cash-settled derivative transactions 
 
 Class of    Product description      Nature of dealing      Number of reference   Price per 
  relevant         e.g. CFD          e.g. opening/closing         securities          unit 
  security                          a long/short position, 
                                     increasing/reducing 
                                    a long/short position 
    N/A              N/A                     N/A                     N/A              N/A 
            --------------------  ------------------------  --------------------  ---------- 
 
   (c)        Stock-settled derivative transactions (including options) 
   (i)         Writing, selling, purchasing or varying 
 
Class of      Product        Writing,         Number        Exercise    Type e.g.    Expiry      Option 
 relevant    description    purchasing,    of securities    price per    American,    date     money paid/ 
 security     e.g. call      selling,        to which         unit       European               received 
               option         varying         option                       etc.                 per unit 
                               etc.           relates 
   N/A          N/A            N/A             N/A            N/A          N/A        N/A         N/A 
           -------------  -------------  ---------------  -----------  -----------  -------  ------------- 
 
   (ii)        Exercise 
 
 Class of    Product description   Exercising/   Number of securities   Exercise price 
  relevant     e.g. call option     exercised                              per unit 
  security                           against 
    N/A              N/A               N/A               N/A                 N/A 
            --------------------  ------------  ---------------------  --------------- 
 
   (d)        Other dealings (including subscribing for new securities) 
 
 Class of relevant    Nature of dealing    Details    Price per unit 
      security        e.g. subscription,              (if applicable) 
                          conversion 
        N/A                  N/A             N/A           N/A 
                    --------------------  --------  ----------------- 
 
   3.         OTHER INFORMATION 
   (a)        Indemnity and other dealing arrangements 
 
 Details of any indemnity or option arrangement, or any agreement or understanding, 
  formal or informal, relating to relevant securities which may be an inducement to deal 
  or refrain from dealing entered into by the exempt principal trader making the 
  disclosure and any party to the offer or any person acting in concert with a party to the 
  offer: 
  Irrevocable commitments and letters of intent should not be included. If there are no such 
  agreements, arrangements or understandings, state "none" 
 
   NONE 
 
    (b)       Agreements, arrangements or understandings relating to options or derivatives 
 
 Details of any agreement, arrangement or understanding, formal or informal, between 
  the exempt principal trader making the disclosure and any other person relating to: 
  (i) the voting rights of any relevant securities under any option; or 
  (ii) the voting rights or future acquisition or disposal of any relevant securities to which 
  any derivative is referenced: 
  If there are no such agreements, arrangements or understandings, state "none" 
 
   NONE 
 
 
 Date of disclosure:    10 JANUARY 2019 
 Contact name:          Craig Horsley 
                       ------------------ 
 Telephone number:      +44(141) 245 7736 
                       ------------------ 
 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

FERCKKDNNBKDFDD

(END) Dow Jones Newswires

January 10, 2019 08:40 ET (13:40 GMT)

1 Year Takeda Pharmaceutical Chart

1 Year Takeda Pharmaceutical Chart

1 Month Takeda Pharmaceutical Chart

1 Month Takeda Pharmaceutical Chart

Your Recent History

Delayed Upgrade Clock